Abstract:Abstract There are two quinone reductases that occur in mammalian systems NAD(P)H:quinone oxidoreductase 1 (NQO1, EC 1.6.99.2) and NRH:quinone oxidoreductase 2 (NQO2, EC 1.10.99.2). NQO1 has been shown to be up-regulated in many types of human solid cancer; whereas NQO2 has been shown to be highly expressed in leukemias. In order to explore their potential as therapeutic targets, we have developed potent and selective mechanism-based inhibitors for both enzymes centered on the indolequinone pharmacophore. Previously, we characterized ES936 (5-methoxy-1,2-dimethyl-3-(4-nitrophenoxy)methylindole-4,7-dione) as an efficient mechanism-based inhibitor of NQO1 and we have now developed a series of indolequinones as mechanism-based inhibitors of NQO2. Substitution of the 5-methoxy group in ES936 with an aminoalkylamino side chain generated potent mechanism-based inhibitors of NQO2 that did not efficiently inhibit NQO1. NQO2 inhibition was observed with compounds with 5’-aminoalkyl chains that varied from 3 to 8 carbons in length, with maximal inhibition observed with compounds that possessed 5’-chain lengths of between 3 to 5 carbons. Compounds with substitutions at the 6-position were not efficient mechanism-based inhibitors of NQO2. As previously observed for a series of NQO1 mechanism-based inhibitors, structural requirements for efficient inhibition of NQO2 also included a substituent at the 3-position capable of leaving to generate a reactive iminium electrophile following enzymatic reduction. Selected indolequinones were tested for NQO2 inhibition using the human leukemia cell line K562 and were found to inhibit NQO2 activity in K562 cells at nanomolar concentrations while not affecting NQO1 activity. Computational-based molecular modeling simulations demonstrated the substantial difference between the active site of NQO1 and NQO2 and ESI-LC/MS provided possible explanations for selective enzyme inhibition. These indolequinones represent the first mechanism based inhibitors of NQO2 to be characterized. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2581. doi:10.1158/1538-7445.AM2011-2581

Design, Synthesis, and Biological Evaluation of Evodiamine-Indolequinone Hybrids As Novel NQO1 Agonists Against Non-Small Cell Lung Cancer

Design, Synthesis, and Biological Evaluation of NAD(P)H: Quinone Oxidoreductase (Nqo1)-Targeted Oridonin Prodrugs Possessing Indolequinone Moiety for Hypoxia-Selective Activation.

Design, synthesis and bioactivity evaluation of the combination of evodiamine and erlotinib linked by indolequinone

Development of Novel Amino-Quinoline-5,8-dione Derivatives As NAD(P)H:quinone Oxidoreductase 1 (NQO1) Inhibitors with Potent Antiproliferative Activities

Design, Synthesis and Biological Evaluation of 6-(Nitroimidazole-1h-alkyloxyl)-4-anilinoquinazolines As Efficient EGFR Inhibitors Exerting Cytotoxic Effects Both under Normoxia and Hypoxia.

Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.

Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.

2-Substituted 3,7,8-Trimethylnaphtho[1,2-b]furan-4,5-diones As Specific L-shaped NQO1-mediated Redox Modulators for the Treatment of Non-Small Cell Lung Cancer.

Synthesis And Biological Evaluation Of 3-Aryl-Quinoxaline-2-Carbonitrile 1,4-Di-N-Oxide Derivatives As Hypoxic Selective Anti-Tumor Agents

Synthesis and in Vitro Anticancer Activity of 6,7-Methylenedioxy (or 5-Hydroxy-6-methoxy)-2-(substituted Selenophenyl)Quinolin-4-One Analogs

Synthesis and Biological Evaluation of Novel 2-Amino-1,4-Naphthoquinone Amide-Oxime Derivatives as Potent IDO1/STAT3 Dual Inhibitors with Prospective Antitumor Effects

Novel NQO1 Substrates Bearing Two Nitrogen Redox Centers: Design, Synthesis, Molecular Dynamics Simulations, and Antitumor Evaluation.

Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.

Design, Synthesis and Structure-Activity Relationship Study of Novel Naphthoindolizine and Indolizinoquinoline-5,12-dione Derivatives As IDO1 Inhibitors

Design and Synthesis of NAD(P)H: Quinone Oxidoreductase (Nqo1)-Activated Prodrugs of 23-Hydroxybetulinic Acid with Enhanced Antitumor Properties.

Design, Synthesis and Antiproliferative Activity of a Novel Class of Indole-2-carboxylate Derivatives.

Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects Through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3.

Discovery of proqodine A derivatives with antitumor activity targeting NAD(P)H: quinone oxidoreductase 1 and nicotinamide phosphoribosyltransferase

Design, synthesis and biological evaluation of novel hybrids of quinazoline derivatives and phenylsulfonylfuroxan as potential anti-tumor agents

Novel Indolyl-Chalcone Derivatives Inhibit A549 Lung Cancer Cell Growth Through Activating Nrf-2/Ho-1 and Inducing Apoptosis in Vitro and in Vivo

Abstract 2581: Indolequinone Mechanism-Based Inhibitors of Quinone Reductases: Structural Basis for Selective Inhibition of NQO2 Relative to NQO1